Selank is built from tuftsin, a short piece of an antibody. Research asks what that sequence does to the brain's main calming signal.
Selank · Tuftsin-derived neuropeptide
The brain balances excitation with inhibition. GABA is the chemical messenger that does most of the calming: when it binds its receptor, nerve cells become harder to fire. Many anxiety medicines work by strengthening that signal. Selank is studied for whether a peptide can influence the same system. Most of the evidence is from rat brain tissue and cultured cells, with a small number of Russian clinical studies.
Selank is a synthetic heptapeptide, seven amino acids: Thr-Lys-Pro-Arg-Pro-Gly-Pro. The first four residues are tuftsin, a naturally occurring fragment of immunoglobulin G, the most common antibody in blood. Tuftsin's known role is in immune cells, where it encourages phagocytosis, the engulfing of foreign material. The Pro-Gly-Pro tail was added at the Institute of Molecular Genetics of the Russian Academy of Sciences to slow the peptide's breakdown by enzymes.
The mechanism proposed for its effects on behaviour involves GABA-A receptors, the receptors that mediate fast inhibition in the brain. In binding studies on rat brain membranes, Vyunova and colleagues (2018) reported that Selank altered GABA binding in the manner of a positive allosteric modulator, a molecule that attaches to a receptor at a second site and makes the main signal work more strongly. That is a hypothesis about mechanism drawn from laboratory chemistry, not a demonstrated action in the human brain.
Laboratory work has looked at gene expression. Volkova and colleagues (2016) measured 84 neurotransmission-related genes in rat frontal cortex one and three hours after Selank or GABA and found overlapping changes, which they read as consistent with an effect on the GABA system. In cultured human neuroblastoma cells, Filatova and colleagues (2017) found that Selank alone did not change those genes, but altered the response to GABA, a result that only partly supports the hypothesis.
The human evidence is a small clinical literature from Russia, published largely in Russian. Medvedev and colleagues (2014) compared Selank with the benzodiazepine phenazepam in 60 patients with anxiety and somatoform disorders and reported an anxiolytic effect that persisted for a week after treatment ended. The abstract describes a comparative design but not randomisation, blinding or a placebo arm, and outcome measures are not specified there. Those design features, rather than the language of publication, are what limit how much weight the result can carry. The trial groups are affiliated with the institute that developed the peptide, and independent replication has not been identified for this note.
Selank is not an approved medicine in Australia, the United States or the European Union. Its clinical use in the published studies is within the Russian healthcare system.
The link between GABA-receptor binding in rat membranes and behaviour in people has not been closed. It is not known whether intranasal Selank, the route used clinically in Russia, reaches the human brain in amounts that change receptor activity. The clinical studies are small, single-country, mostly unblinded as far as their abstracts show, and conducted by groups connected to the developer. Whether the persisting effect reported after treatment reflects the peptide, regression to the mean or expectation cannot be settled from that design. No long-term safety data in people have been identified.
Selank is not listed by name in the current Poisons Standard (June 2026) and is not an approved medicine in Australia; it has no FDA or EMA approval.
Sources and status checked 2026-09-22
Selank — sizes and pricing